Tocilizumab and Sarilumab reduced the relative risk of death from Covid-19 by 24%

Coronavirus, England, Europe, Health, Northern Ireland, Science, Scotland, Treatment, UK, Wales

NHS patients to receive life-saving COVID-19 treatments that could cut hospital time by 10 days.

Clinical trial results show the drugs reduce risk of death by 24% for critically ill patients and time spent in intensive care by up to 10 days.

Patients across the UK who are admitted to intensive care units due to COVID-19 are set to receive new life-saving treatments which can reduce the time spent in hospital by up to 10 days, the government has announced today (Thursday 7 January).

Results from the government-funded REMAP-CAP clinical trial published today showed tocilizumab and sarilumab reduced the relative risk of death by 24%, when administered to patients within 24 hours of entering intensive care.


Image by Sasin Tipchai from Pixabay

** This post was originally published on January 7, 2021 **